The von Hippel-Lindau tumor suppressor protein (pVHL) suppresses tumor formation by binding the a subunits of hypoxiainducible-factors responsible for stimulating tumor angiogenesis and glycolysis, and targeting them for ubiquitination and proteasomal destruction. Loss of pVHL leads to tumorigenesis and development of sporadic renal cell carcinomas and central nervous system hemangioblastomas. In the present study, we investigated whether engineered overexpression of pVHL in C6 glioma cells, which already express endogenous pVHL, would suppress the tumorigenicity of this particular tumor cell type. C6 cells overexpressing VHL displayed a reduced growth rate (70% inhibition) compared to the parental cell line when subcutaneously implanted in athymic (nu/nu) mice. Growth inhibition was associated with a 50% reduction in the number of tumor vessels and a 60% increase in tumor cell apoptosis, due in part to downregulation of HIF-1, VEGF, and the antiapoptotic factor Bcl-2, respectively. Gene transfer of VHL suppressed the growth of established C6 gliomas, and synergized with antisense HIF-1 to completely eradicate tumors. The data suggest that VHL gene therapy and/or agents that increase VHL expression could have utility in the treatment of gliomas, particularly when combined with agents that inhibit the expression or function of HIF-1.
Introduction
Gliomas encompass all tumors of the central nervous system (CNS). Despite multimodality treatments including surgery, radiation, and chemotherapy, the mean survival time for patients with glioma is still approximately only 1 year from the time of diagnosis. 1 These traditional therapeutic modalities are ultimately ineffective in curing gliomas, due to the radioresistance of glioma cells and the difficulty of achieving complete tumor resection. There is therefore an urgent need to devise alternative therapeutic strategies for the treatment of gliomas.
Somatic mutations of the von Hippel-Lindau (VHL) tumor suppressor gene are often detected in sporadic cases of renal cell carcinoma (RCC) 2 and CNS hemangioblastomas. 3 They have also recently been identified in human colorectal carcinomas. 4 Germline mutations in the VHL gene, and somatic inactivation or loss of the remaining wild-type VHL allele are linked to tumor formation, as the von Hippel-Lindau protein (pVHL) mediates an important control mechanism for tumorigenesis and angiogenesis. pVHL activates the ubiquitin-mediated degradation pathway and targets hypoxia-inducible factor-1 (HIF-1) for destruction. 5, 6 Thus, functional inactivation of VHL stimulates tumor formation, in part, by increasing the stability of HIF-1.
3,7 HIF-1 regulates cellular adaptation to changes in oxygen availability by activating genes involved in angiogenesis, erythropoiesis, energy and iron metabolism, tissue matrix metabolism, and cell survival decisions, which are key factors for tumor growth and survival. [8] [9] [10] A 35 amino-acid residue subdomain of the a domain of pVHL binds elongin C, which recruits additional proteins including elongin B, cullin-2, the RING-H2 protein Rbx1/Roc1, and ubiquitin -conjugating enzyme E2, to form a ubiquinating complex. The b domain of pVHL binds the a subunits of HIF-1 and HIF-2, targeting them for ubiquitination and proteasomal destruction in a VHL a-domain-dependent manner. 11 The binding of HIF-1a subunits to VHL, and their rapid degradation by the VHL ubiquitinating complex under normoxic conditions, is regulated by oxygen and irondependent hydroxylation of Pro-564 within HIF-1a.
formation of a VHL ubiquitinating complex, and or binding to HIF-1, respectively, leading to stabilization of HIF-1. 8, 12 A hypoxic phenotype results in which increased levels of HIF-1 induce the synthesis of hypoxia-inducible genes such as vascular endothelial growth factor (VEGF), platelet-derived growth factor, and glucose transporter-1 (Glut-1), which assist tumor growth by stimulating tumor angiogenesis, and metabolism. [13] [14] [15] C6 glioma cells have been shown to respond to hypoxia by inducing hypoxia-inducible pathways. 16 Thus, conditioned medium for C6 cells contains significantly increased levels of the HIF-1 effectors basic fibroblast growth factor (bFGF) and VEGF. 17 The expression of VEGF is upregulated in C6 cells by hypoxia in vitro, 18 and in C6 glioma tumors, 19 due to both transcriptional activation and increased stability of VEGF mRNA. Human glial tumors contain somatic mutations in the VHL gene, and there is loss of heterozygosity of the VHL gene. 20 VHL is expressed in neurons of the CNS and plays an important role during the neuronal differentiation of CNS progenitor cells. VHL protein can transform human neuroblastoma cells into functional neuron-like cells, whereas conversely inhibition of expression of endogenous VHL protein using an antisense VHL gene inhibited neuronal differentiation and increased cell cycling. 2, 21 These studies suggest that restoration of the function of VHL could be used to combat gliomas in which VHL function is impaired.
We have previously demonstrated that overexpression of VHL suppresses the growth of lymphomas, which are not known to carry germline mutations in the VHL gene. This result was surprising as it suggests that tumors other than those that carry VHL-deficiencies, such as RCC which is dependent on VHL for growth, could be susceptible to VHL therapy. Further, VHL therapy synergized with antisense HIF-1 to bring about the complete eradication of lymphomas. 22 In the present study we investigated whether overexpression of VHL alone or in combination with antisense HIF-1a could inhibit the tumorigenesis of C6 gliomas, and suppress the growth of established C6 gliomas.
Materials and methods
Mice, cell lines, and antibodies Male, 6-8 weeks old, athymic (nu/nu) mice were obtained from the Animal Research Center, Shandong University, China. Rat glioma C6 cells were purchased from the American Type Culture Collection (Rockville, MD). The antibodies used in the study include anti-FLAG mAb (Sigma, MO), rabbit polyclonal antibodies against a peptide corresponding to the N-terminus (amino-acid residues 1-181) of VHL (FL-181; Santa Cruz Biotechnology, Inc., CA), anti-HIF-1a mAb (H1a67; Novus Biologicals, Inc., Littleton, CO), rabbit polyclonal antibodies against VEGF (Ab-1; Lab Vision Corporation; CA), and an anti-CD31 mAb (MEC13.3; Pharmingen, CA).
Construction of expression plasmids
The mouse VHL gene was amplified from a previously reported VHL-pcDNA3 plasmid 22 using the primers 5 0 -GG GTA CTG CTG CTC TGG GTT CCA GGT TCC ACT GGT GAC CCC CGG AAG GCA GCC AG-3 0 and 5 0 -GGG GGA TCC TCA CTT ATC ATC ATC ATC CTT GTA ATC AGG CTC CTC TTC CAG GTG CTG-3 0 . The resulting PCR product was used as a template for further amplication with the primers 5 0 -GAA GCT TAT GGA GAC AGA CAC ACT CCT GCT ATG GGT ACT GCT GCT CTG GG-3 0 and 5 0 -GGG GGA TCC TCA CTT ATC ATC ATC ATC CTT GTA ATC AGG CTC CTC TTC CAG GTG CTG-3 0 . The final PCR product was subcloned into the pCDNA3.1 expression vector to encode a 5 0 signal peptide from the mouse kappa light chain antibody fused to the second amino-acid residue (proline) of the VHL gene, the full-length mouse VHL gene (GenBank accession number AF513984), and a Cterminal FLAG epitope (DYKDDDDK) that allows the detection of recombinant VHL with an anti-FLAGspecific mAb (Figure 1a) . A pcDNA3 expression vector encoding an antisense version of the 5 0 -end of mouse HIF1a (nucleotides 152-454; GenBank accession number AF003695) has been described previously. 23 All constructs were verified by DNA sequence analysis.
Establishment and analysis of glioma C6 cells stably expressing VHL C6 cells were routinely cultured at 371C in RPMI 1640 supplemented with 10% fetal calf serum, and 2 mM Lglutamine. Cells were seeded in 10 cm plastic dishes and grown to 66% confluence at which point they were transfected with 4 mg of plasmid using lipofectamine PLUSt (Life Technologies, China). Cells were detached with trypsin after transfection for 72 h, and seeded at a dilution of 1:20 in selection medium containing 1.2 mg/ml of neomycin G418. Stable transfectants were selected at 3 weeks of culture.
Total protein from the conditioned media of stable VHL transfectants was precipitated with 8 volumes of chilled 100% (v/v) methanol by incubation overnight at À201C and samples centrifuged at 800 g for 15 min at room temperature. The protein pellets were resuspended in PBS containing several standard protease inhibitors. For analysis of cell lysates, cell monolayers of stable VHL transfectants were lysed on ice with lysis buffer (50 mM Tris-Cl, pH 7.5, containing 1% v/v Triton-X, 15% v/v deoxycholic acid, 0.5 M NaCl, and 1 mM EDTA). Concentrated conditioned medium and cell lysates were subjected to Western blot analysis as described previously. 22, 23 Briefly, concentrated conditioned medium and cell lysates were resolved on 10% polyacrylamide SDS gels, and electrophoretically transferred to nitrocellulose Hybond C extra membranes (Amersham Life Science, England). The membranes were blocked with 5% (w/v) BSA, and then incubated with specific primary Abs followed by horseradish peroxidase-conjugated secondary antibodies. The blots were developed by enhanced chemiluminescence (Amersham International plc, England) and exposed to X-Ray film.
Subcellular fractionation
Subcellular fractions of C6 VHL transfectants were separated by centrifugation on Percoll gradients. Cells were suspended in disruption buffer (10 mM HEPES containing 250 mM sucrose, 0.3 mM Na-EDTA and the proteinase inhibitors aprotinin (1 mg/ml), leupeptin (0.5 mg/ml), pepstatin A (1 mg/ml), and PMSF (0.1 mg/ ml)). They were disrupted by nitrogen cavitation (350 psi, 5 min), and the cavitate was collected dropwise into 1.5 mM EGTA (pH 7.4). Nuclei were sedimented by centrifugation at 500 g for 10 min at 41C. To isolate secretory vesicles, the postnuclear supernatant (cytosolic fraction) was mixed with a Percoll solution (1.12 g Percoll/ ml), and layered under a less dense Percoll solution (1.04 g Percoll/ml). A further buffer (10 mM PIPES, pH 7.3, containing 100 mM KCl, 3 mM NaCl, 1 mM ATP(Na) 2 , and 3.5 mM MgCl 2 ) was applied uppermost. A gradient was formed by centrifugation at 37 000 g for 35 min at 41C using a fixed-angle Beckman JA-20 rotor. After centrifugation, the secretory vesicles were collected by aspiration from the bottom of the tube. The nuclei, cytosolic fraction, secretory vesicles, as well as whole-cell lysates were incubated on ice with lysis buffer and subjected to Western blot analysis with an anti-Flag mAb as described above. Band density was quantified using Scion Image software (Scion Corporation, Frederick, MD). The relative amount of exogenous pVHL in each subcellular fraction was calculated by dividing the band density of each fraction by the band density generated by the whole cell lysate. The relative amount of pVHL in the cytoplasm (free of secretory vesicles) ¼ pVHL in cytosolic fraction ÀpVHL in secretory vesicles.
In vitro cell proliferation assay
To determine whether the therapeutic expression plasmids affected tumor cell growth in vitro, parental C6, C6 VHL , and C6 EMPTY cells were seeded at 100 cells/well into 24-well culture plates. Cells were detached with trypsin and cell numbers were enumerated using a hemacytometer.
Model of subcutaneous glioma in nude mice
Nude mice were subcutaneously implanted with 1 Â 10 6 parental C6, C6 EMPTY , or C6 VHL glioma cells. All surgical procedures and care administered to the animals was in accordance with institutional guidelines. Tumors were monitored and measured, and tumor volumes estimated according to the formula V ¼ p/6 Â a 2 Â b, where a is the short axis and b the long axis.
Intratumoral gene therapy
Purified plasmids were diluted to 1 mg/ml in a solution of 5% glucose in 0.01%. Triton X-100, and mixed in a ratio of 1:3 (wt:wt) with DOTAP cationic liposomes (Boehringer Mannheim, Mannheim, Germany). When they reached a volume of B20 mm 3 10 days after cell implantation, tumors were injected with 100 ml of expression plasmid, as described previously. 22 For combinational treatment, reagents were delivered in a timed fashion, where VHL plasmid was injected first, followed by antisense HIF-1a plasmid 24 h later. All experiments included six mice per group, and each experiment was repeated at least once.
Immunohistochemistry
Tumor cryosections (10 mm) were prepared, treated with acetone, rinsed with PBS, and blocked with 2% (w/v) BSA for 2 h. They were incubated overnight with anti-HIF-1a mAb, or rabbit polyclonal antibodies against VEGF, and subsequently incubated for 30 min with appropriate secondary antibodies. The sections were developed with Sigma FAST DAB (3, 3 0 -diaminobenzidine VHL and antisense HIF-1a eradicate gliomas X Sun et al tetrahydrochloride) and CoCl 2 enhancer tablets (Sigma), counterstained with Mayer's hematoxylin, and examined by microscopy.
Assessment of vascularity
Sections (10 mm) were prepared from fresh frozen tumors, and immunostained with the anti-CD31 antibody, as above. The methodology used to assess blood vessel density and to evaluate vascularity (concentric circles method) have been described previously.
22,23
In situ detection of apoptotic cells
The method for detecting apoptotic tumor cells in situ has been described previously. 22, 23 Briefly, serial sections of 6 mm thickness were prepared from tumors. TUNEL staining of sections was performed using an in situ apoptosis detection kit from Boehringer Mannheim, Germany, and sections examined by fluorescence microscopy. The apoptotic index was calculated as the percentage of stained cells, namely AI ¼ number of apoptotic cells Â 100/total number of nucleated cells.
Statistical analysis
Results were expressed as mean values7standard deviation (s.d.), and a Student's t-test was used for evaluating statistical significance. Po0.05 was considered to be statistically significant.
Results

Stable transfection of C6 cells with a VHL plasmid and their growth in vitro
In total, 16 clones stably expressing recombinant VHL were isolated following transfection of rat C6 cells with an expression plasmid encoding a secreted form of VHL. A secreted form of VHL was employed to prevent the potentially toxic build-up of recombinant protein. The transfectants were recombined and defined as C6 VHL , whereas control cells transfected with empty vector were designated as C6 EMPTY . Expression of VHL in the conditioned medium and cell lysates of C6 VHL cells was confirmed by Western blot analysis using anti-FLAG, and anti-VHL antibodies. Recombinant VHL present in conditioned medium and cell lysates was approximately 20-25 kDa in size, as expected (Figure 1b) . A weak band of 18 kDa observed migrating just in front of VHL is probably endogenous VHL. The recombinant VHL protein was expected to be slightly larger than endogenous VHL as it carries an 8 amino-acid FLAG tag (Figure 1b) . The relative amount of exogenous pVHL in cell nuclei, cytoplasm free of secretory vesicles, and secretory vesicles was analyzed by Western blot and compared with the levels in whole-cell lysates, revealing that around 20% of the pVHL was contained within nucleus, 38% in the cytoplasm, and 42% in secretory vesicles (Figure 1c) . The proliferation rate of C6 VHL cells was slightly slower than C6 EMPTY cells or parental C6 cells when they were cultured in vitro; however, the difference was not significant (Figure 1d ).
Growth of transfected C6 cells in athymic mice
Control parental rat C6, C6 empty cells, and C6 VHL cells (i.e. the recombined 16 stable transfectants above) were implanted subcutaneously into athymic nu/nu mice. Tumor volumes were measured every three days (Figure 2a) . Palpable tumors were detected in mice 9 days after implantation of control tumors, and a rapid increase in tumor volumes was observed between 18 and 21 days after implantation. In contrast, tumors arising from C6 VHL 
Downregulation of the expression of HIF-1a and its effector molecule VEGF
In order to further understand the mechanisms responsible for the effects of overexpressed VHL on tumor VHL and antisense HIF-1a eradicate gliomas X Sun et al growth and vascularity, we examined parental C6, C6 EMPTY , and C6 VHL tumors for the levels of HIF-1a, and its effector VEGF. HIF-1a and VEGF expression was downregulated in C6 VHL tumors, in comparison with either of the control tumors as revealed by immunohistochemistry (Figure 3a) , and supported by Western blot analysis (Figure 3b ).
Vascularization and apoptosis of subcutaneous glioma
The level of vascularization of subcutaneous tumors at 21 days after implantation was analyzed. Parental C6 and C6 EMPTY tumors had similar levels of vascularization (Figure 4a ). The vessels were generally of different shapes and sizes. In contrast, the C6 VHL tumors appeared less vascularized compared to control tumors, and the vessels were truncated with thinner vessel walls (Figure 3a ). Both VHL and antisense HIF-1a eradicate gliomas X Sun et al parental C6 and C6 EMPTY tumors had similar numbers of vessels per standard field. In contrast, the number vessels observed in C6 VHL tumors was significantly (Po0.01) reduced by 50% compared to controls (Figure 4a ). The median and 90th percentile distances to the nearest CD31-labeled venules from an array of points within C6 VHL tumors were significantly (both Po0.01) longer than those in parental C6 and C6 EMPTY tumors (Figure 4b ). These data reveal that engineered overexpression of VHL in C6 cells results in significant inhibition of tumor angiogenesis.
The level of apoptosis of subcutaneous tumors 21 days after implantation was determined. Both parental C6 and C6 EMPTY tumors had similar levels of apoptosis, whereas the C6 VHL tumors displayed increased apoptosis (Figure 3a) . Accordingly, parental C6 and C6 EMPTY tumors had similar apoptotic indexes (AI), whereas the AI of C6 VHL tumors was significantly (Po0.01) increased by 60% (Figure 4c ). Thus, engineered overexpression of VHL in C6 cells promotes tumor cell apoptosis.
It has previously been reported that C6 glioma cells express the antiapoptotic factor Bcl-2, 24-26 hence we examined whether VHL-induced apoptosis might be due in part to downregulation of Bcl-2, as demonstrated in an EL-4 lymphoma. 22 As shown in Figure 3b , the expression of Bcl-2 was greatly reduced in C6 VHL gliomas, compared with either parental C6 or C6 EMPTY tumors.
Suppression of tumor growth by intratumoral injection of a VHL expression vector alone and in combination with antisense HIF-1a
Here we investigated whether the VHL expression plasmid might synergize with antisense HIF-1 plasmid in the treatment of already established C6 tumors, as previously demonstrated for lymphoma. 22 Parental C6 cells (1 Â 10 6 ) were subcutaneously injected into the right flank of nude mice, and tumors of B20 mm 3 in size that had formed 10 days later were injected with a DNA/ liposome transfection vehicle containing either 100 mg of empty pCDNA3.1, VHL-pCDNA3.1, antisense HIF-1a-pCDNA3, or VHL-pCDNA3.1 plus antisense HIF-1a-pCDNA3 plasmids. Tumors grew rapidly following injection of empty vector, whereas tumors injected with either VHL or antisense HIF-1a plasmids grew more slowly initially, but after 1 week the growth rate was nearly identical to that of the control tumors ( Figure 5) . In marked contrast, combination therapy with VHL and antisense HIF-1 plasmids led to the complete eradication of established C6 gliomas ( Figure 5 ). Mice were monitored for 31 days following gene injection, but the tumors failed to reappear.
Discussion
Here we have for the first time investigated the tumor suppressor activity of VHL in the rat C6 glioma model. Engineered overexpression of VHL in C6 cells (as illustrated by C6 VHL ) resulted in less vascularization of C6 tumors formed in athymic mice, and the vessels formed were smaller and had thinner walls. Consequently, C6 VHL tumors grew more slowly than parental C6 tumors. Thus, VHL overexpressed in C6 cells exerts antiangiogenic activity. The reduced vascularization exhibited by C6 VHL gliomas was not sufficient to completely suppress tumor growth. VEGF could still be detected, albeit at much lower levels than in control tumors, and was probably responsible for the small numbers of malformed vessels that provided some nourishment to the tumor.
Schraml et al.
27
proposed that VHL's tumor-suppressor activities are, in part, contingent upon its nuclear localization and are independent of cytoplasmic access or regulation of HIF-1a. Previous studies have revealed that VHL resides predominantly in the cytoplasm, 28 but shuttles between the nucleus and cytoplasm, depending on cell density 28 and transcriptional arrest. 29 As cell density increases, VHL shifts from the nucleus to the cytoplasm. Although the expression of wild-type VHL is largely cytoplasmic in RCC cell lines, the ability of VHL to inhibit tumor invasion could be reconstituted by nuclear-localized VHL. 30 Here we have expressed a secreted form of VHL, which is expressed in each of the nuclear, cytoplasmic, and secretory vesicle compartments of the cell, and is nevertheless effective. The nuclear and cytoplasmic localization signals embedded in the VHL sequence, 28 which direct VHL to the nucleus and cytoplasm may over-ride the secretory pathway and allow VHL to be partly expressed free in the cytoplasm and nucleus.
VHL acts as a tumor suppressor by virtue of its ability to influence the stability of HIF-1 by a process involving ubiquitination and proteasomal destruction of HIF-1. In accord, our results demonstrated that overexpression of VHL in situ led to downregulation of HIF-1, which in turn inhibited the expression of its effector VEGF. The inhibition of neovascularization by downregulation of Figure 5 Gene transfer of VHL and antisense HIF-1 in combination eradicates established C6 gliomas. Gliomas were established by subcutaneous injection of 1 Â 10 6 parental C6 cells, reaching around 20 mm 3 10 days after implantation. They were then injected with expression plasmids encoding VHL, antisense HIF-1a, empty vector (Control), or with a VHL expression plasmid followed 24 h later by injection of antisense HIF-1a plasmid (vertical arrow). Tumor size was measured every two days, and tumor volumes presented as the average mm 3 7s.d.
VHL and antisense HIF-1a eradicate gliomas X Sun et al VEGF would restrict the supply of tumor cell survival factors provided either by the endothelial cells or by the blood circulation, creating a bystander effect that would effect protein expression and survival of adjacent tumor cells. There have been several reports that angiogenesis inhibitors can induce tumor cell apoptosis by decreasing endothelial cell proliferation, 31 and the levels of endothelial-cell-derived paracrine factors that promote cell survival. 32 There are various other mechanisms by which VHL may inhibit tumor growth. VHL may have a more predominant role in regulating cell survival, and in accord tumor apoptosis was increased in C6 VHL gliomas in the present study, as previously reported in a study of the EL-4 lymphoma. 22 A number of studies have attempted to address the mechanisms by which VHL induces the apoptosis of RCC cells. 33 The present study reveals that VHL-mediated apoptosis of C6 glioma cells is accompanied by downregulation of Bcl-2. VHL is a multifunctional tumor suppressor protein exerting effects on hormone levels, 34 the extracellular matrix, [35] [36] [37] cell differentiation 38 and growth, 39 protease and protease inhibitor secretion, 40 the cytoskeleton and cell motility and invasiveness, mRNA stability, 41 the cell cycle, 42 and cell signaling, 43 all of which may play a role in the antitumour activity of VHL.
We have demonstrated here that combining antisense HIF-1a therapy with VHL therapy results in the complete regression of C6 tumors. We propose that the combined affect of inhibiting the several signaling pathways mediated by HIF-1 and VHL is enough to cripple tumor cells, depriving them of key factors required for growth and survival. The potent antitumor effect of combined VHL and antisense HIF-1a therapy appears to be largely independent of a functioning immune system, as the current study employed athymic (nu/nu) mice that are deficient in functional T cells.
In summary, the present study demonstrates that engineered overexpression of VHL by C6 gliomas downregulates their expression of HIF-1a and VEGF, thereby inhibiting tumor angiogenesis and increasing apoptosis, which consequently leads to delayed tumorigenesis. Furthermore, VHL gene therapy synergized with antisense HIF-1a to eradicate already established C6 gliomas. Combinational treatment regimes that target both HIF-1 and VHL or other molecules related to these pathways such as the newly described VLP protein 44 may hold greater utility in treating solid tumors in humans than the respective monotherapies.
